Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3
The event will follow the Company’s key data presentations at the 60th
A webcast replay of the event will be available on the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The Company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T, TCR and allogeneic T cell therapies. Its lead product candidate, rivo-celTM, is an allogeneic polyclonal T cell therapy that has shown promising clinical trial results in reducing leukemia relapse after a stem cell transplant. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information can be found at www.bellicum.com.
Investors: Solebury Trout
Chad Rubin646-378-2947 firstname.lastname@example.org Media: Solebury Trout Brad Miles646-513-3125 email@example.com
Source: Bellicum Pharmaceuticals, Inc.